Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer

ConclusionPatients withKRAS-mutant lung adenocarcinoma have a poorer outcome on pemetrexed-based first-line chemotherapy. WhetherKRAS-mutant NSCLCs should be excluded from pemetrexed-containing regimens should be assessed prospectively.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research